Monopar Therapeutics Inc (MNPR) concluded trading on Thursday at a closing price of $32.66, with 19.49 million shares of worth about $636.54 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 940.96% during that period and on October 24, 2024 the price saw a gain of about 605.40%. Currently the company’s common shares owned by public are about 2.98M shares, out of which, 1.76M shares are available for trading.
Stock saw a price change of 471.98% in past 5 days and over the past one month there was a price change of 531.72%. Year-to-date (YTD), MNPR shares are showing a performance of 1820.05% which increased to 1299.91% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.37 but also hit the highest price of $8.65 during that period. The average intraday trading volume for Monopar Therapeutics Inc shares is 812.93K. The stock is currently trading 389.03% above its 20-day simple moving average (SMA20), while that difference is up 613.44% for SMA50 and it goes to 800.84% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Monopar Therapeutics Inc (NASDAQ: MNPR) currently have 2.98M outstanding shares and institutions hold larger chunk of about 2.16% of that.
The stock has a current market capitalization of $114.96M and its 3Y-monthly beta is at 1.27. It has posted earnings per share of -$2.30 in the same period. It has Quick Ratio of 6.59 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MNPR, volatility over the week remained 146.71% while standing at 44.48% over the month.
Stock’s fiscal year EPS is expected to drop by -86.15% while it is estimated to decrease by -20.18% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Rodman & Renshaw on October 11, 2024 offering a Buy rating for the stock and assigned a target price of $50 to it. Coverage by ROTH Capital stated Monopar Therapeutics Inc (MNPR) stock as a Buy in their note to investors on January 28, 2021, suggesting a price target of $49 for the stock.
